Exicure Revenue 2011-2026 | XCUR

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Exicure

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	500 K	-	28.8 M	-483 K	16.6 M	1.3 M	118 K	9.72 M	1.04 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
28.8 M	-483 K	7.2 M

Quarterly Revenue Exicure

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	500 K	-	-	-	-	-	2.02 M	2.47 M	2.56 M	-	-3.68 M	79 K	997 K	140 K	2.44 M	4.85 M	9.18 M	310 K	527 K	434 K	25 K	6 K	57 K	19 K	36 K	2.1 M	2.5 M	2.7 M	2.43 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
9.18 M	-3.68 M	1.42 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
BioLineRx Ltd. BLRX	28.9 M	$ 2.25	1.81 %	$ 908 M	Israel
BioNTech SE BNTX	482 M	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Alnylam Pharmaceuticals ALNY	3.71 B	$ 330.34	3.6 %	$ 43.3 B	USA
CollPlant Biotechnologies Ltd. CLGN	15.6 M	$ 0.44	-16.64 %	$ 5.04 M	Israel
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Catalyst Pharmaceuticals CPRX	589 M	$ 24.98	1.17 %	$ 3.05 B	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Corbus Pharmaceuticals Holdings CRBP	882 K	$ 10.14	-0.29 %	$ 135 M	USA
Cardiff Oncology CRDF	593 K	$ 1.58	-	$ 106 M	USA
Curis CRIS	9.44 M	$ 0.53	-3.07 %	$ 6.98 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Crinetics Pharmaceuticals CRNX	7.7 M	$ 37.7	1.26 %	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	3.51 M	$ 49.15	-0.73 %	$ 4.42 B	Schweiz
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
CytomX Therapeutics CTMX	76.2 M	$ 4.4	-3.51 %	$ 607 M	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Citius Pharmaceuticals CTXR	90 K	$ 0.86	0.67 %	$ 5.79 M	USA
Cue Biopharma CUE	27.5 M	$ 0.18	-1.61 %	$ 17.1 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.09	-0.97 %	$ 437 M	USA
Cyclerion Therapeutics CYCN	2 M	$ 4.15	-32.52 %	$ 10.4 M	USA
Daré Bioscience DARE	1.03 M	$ 1.81	4.02 %	$ 20.2 M	USA
DBV Technologies S.A. DBVT	5.64 M	$ 20.36	-3.32 %	$ 2.84 B	France
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 8.22	2.37 %	$ 225 M	Israel
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Denali Therapeutics DNLI	331 M	$ 19.38	-6.15 %	$ 3.19 B	USA
Dyadic International DYAI	3.09 M	$ 0.87	-2.8 %	$ 31.5 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Celldex Therapeutics CLDX	1.54 M	$ 31.37	1.0 %	$ 2.08 B	USA
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA